Browsing by Author "Hardy-Werbin, Max"

Sort by: Order: Results:

  • Rocha, Pedro P.; Ramal, Didac; Ripoll, Enric; Moliner, Laura; Corbera-Lloret, Alex; Hardy-Werbin, Max; Orrillo, Mayra; Taus García, Álvaro; Zuccarino, Flavio; Gibert Fernandez, Joan, 1988-; Perera Bel, Júlia; Casadevall Aguilar, David; Arriola Aperribay, Edurne (Elsevier, 2020)
    Introduction: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, ...
  • Clavé Safont, Sergi; Salido Galeote, Marta; Gibert Fernandez, Joan, 1988-; Hardy-Werbin, Max; Rocha, Pedro P.; Riera, Xènia; Torres, Erica; Taus García, Álvaro; Pijuan Andujar, Lara; Bellosillo Paricio, Beatriz; Arriola Aperribay, Edurne (Frontiers, 2023)
    Introduction: Next-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead to the better characterization of a tumor's molecular ...
  • Montero, Maria Milagro; Hardy-Werbin, Max; Gonzalez-Gallardo, Soledad; Torres, Erica; Rueda, Rebeca; Arenas-Miras, María Del Mar; Arietta-Aldea, Itziar; Castañeda, Silvia; Gómez Junyent, Joan; Gómez-Zorrilla, Silvia; Guerri-Fernandez, Robert; Sánchez-Martínez, Francesca; López Montesinos, Inmaculada; Pelegrín, Iván; Sendra, Elena; Sorlí, Luisa; Villar García, Judit; Bellosillo Paricio, Beatriz; Horcajada Gallego, Juan Pablo (Nature Research, 2023)
    Tools for the evaluation of COVID-19 severity would help clinicians with triage decisions, especially the decision whether to admit to ICU. The aim of this study was to evaluate SeptiCyte RAPID, a host immune response assay ...
  • Hardy-Werbin, Max; del Rey-Vergara, Raúl; Galindo-Campos, Miguel A.; Moliner Jiménez, Laura; Arriola Aperribay, Edurne (MDPI, 2019)
    Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies ...
  • Hardy-Werbin, Max; Maiques Llácer, José María; Busto Barrera, Marcos; Cirera Lorenzo, Isabel; Aguirre Tejedo, Alfons; García Gisbert, Nieves, 1994-; Zuccarino, Flavio; Carbullanca Toledo, Santiago; Carpio, Luis Alexander del; Ramal, Didac; Gayete, Ángel; Martínez Roldán, Jordi; Márquez Colomé, Albert; Bellosillo Paricio, Beatriz; Gibert Fernandez, Joan, 1988- (Nature Research, 2023)
    The rapid spread of the severe acute respiratory syndrome coronavirus 2 led to a global overextension of healthcare. Both Chest X-rays (CXR) and blood test have been demonstrated to have predictive value on Coronavirus ...
  • Hardy-Werbin, Max; Quiroga, Vanesa; Cirauqui, Beatriz; Romeo, Margarita; Felip, Eudald; Teruel, Iris; García, Juan José; Erasun, Carlos; España, Sofia; Cucurull, Marc; Montprad, Elisabeth; Pardo, Juan Carlos; Carballo, Dania; Velarde, José María; Margeli, Mireia (Nature Research, 2019)
    T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic ...
  • Hardy-Werbin, Max; Rocha, Pedro P.; Arpí Llucià, Oriol; Taus García, Álvaro; Nonell Mazelon, Lara, 1972-; Duran Jordà, Xavier, 1974-; Villanueva, Xavier; Joseph-Pietras, Debora; Nolan, Luke; Danson, Sarah; Griffiths, Richard; López-Botet, M. (Miguel); Rovira Guerín, Ana; Albanell Mestres, Joan; Ottensmeier, Christian; Arriola Aperribay, Edurne (Taylor & Francis, 2019)
    Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking